Patents Assigned to Exicure, Inc.
  • Publication number: 20220064649
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: April 15, 2021
    Publication date: March 3, 2022
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Publication number: 20210269806
    Abstract: The invention in some aspects relates to antisense inhibitors of IL1B and related methods of use. The antisense inhibitors may be formulated as a nanoparticle or other type of three dimensional presentation format.
    Type: Application
    Filed: June 20, 2019
    Publication date: September 2, 2021
    Applicant: Exicure, Inc.
    Inventor: Bart Anderson
  • Publication number: 20210102211
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 8, 2021
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Patent number: 10894963
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 19, 2021
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20210002640
    Abstract: Compositions related to spherical nucleic acids (SNAs) and structures with antisense oligonucleotides and methods of treatment of diseases and disorders are disclosed herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Applicant: Exicure, Inc.
    Inventors: Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla, Michael Mutolo
  • Patent number: 10837018
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 17, 2020
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20200339989
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as GGG. Related methods are also described.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 29, 2020
    Applicant: Exicure, Inc.
    Inventors: Weston Daniel, Scott Mix
  • Publication number: 20200339996
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Application
    Filed: July 16, 2020
    Publication date: October 29, 2020
    Applicant: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Patent number: 10792251
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: October 6, 2020
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Publication number: 20200308579
    Abstract: Aspects of the invention relate to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R), and other targets. Spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment are also provided.
    Type: Application
    Filed: May 5, 2017
    Publication date: October 1, 2020
    Applicant: Exicure, Inc.
    Inventor: Richard Kang
  • Publication number: 20200297867
    Abstract: The invention relates to a method of synthesizing liposomes and liposomal spherical nucleic acids with hydrophobic molecules functionalized to the surface. The lipid particles contain one or more agents that elicit an immune response.
    Type: Application
    Filed: February 1, 2017
    Publication date: September 24, 2020
    Applicant: Exicure, Inc.
    Inventors: Richard Kang, Sagar Anantatmula, Rishika Agarwal, Merideth Burkhart, Bart Anderson
  • Patent number: 10760080
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or Initial Screen of Phosphodiester disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: September 1, 2020
    Assignee: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Publication number: 20200255837
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 13, 2020
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Patent number: 10704043
    Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: July 7, 2020
    Assignee: Exicure, Inc.
    Inventors: Weston Daniel, Scott Mix
  • Publication number: 20200188521
    Abstract: Spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides are described herein. Compositions of the SNA include discrete nanostructures that are not aggregated. Related methods are also described.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 18, 2020
    Applicant: Exicure, Inc.
    Inventors: Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla
  • Publication number: 20200069587
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 5, 2020
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Patent number: 10434064
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 8, 2019
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20190225968
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: July 25, 2019
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Publication number: 20190211338
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Application
    Filed: January 16, 2019
    Publication date: July 11, 2019
    Applicant: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Publication number: 20190142739
    Abstract: Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 16, 2019
    Applicant: Exicure, Inc.
    Inventors: Pinal Patel, Bart Anderson